These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16052800)

  • 1. [The analysis of I125 brachytherapy complications in cases of uveal melanoma].
    Pogrzebielski A; Starzycka M; Romanowska-Dixon B; Jakubowska B; Szpakowicz U
    Klin Oczna; 2005; 107(1-3):49-53. PubMed ID: 16052800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular complications after iodine brachytherapy for large uveal melanomas.
    Puusaari I; Heikkonen J; Kivelä T
    Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I; Heikkonen J; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
    Detorakis ET; Engstrom RE; Wallace R; Straatsma BR
    Ophthalmology; 2005 Mar; 112(3):505-10. PubMed ID: 15745782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.
    Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
    Br J Ophthalmol; 1996 Aug; 80(8):732-9. PubMed ID: 8949719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control.
    Quivey JM; Augsburger J; Snelling L; Brady LW
    Cancer; 1996 Jun; 77(11):2356-62. PubMed ID: 8635107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 125I plaque brachytherapy for anterior uveal melanomas.
    Lumbroso-Le Rouic L; Charif Chefchaouni M; Levy C; Plancher C; Dendale R; Asselain B; Solignac S; Mazal A; Desjardins L
    Eye (Lond); 2004 Sep; 18(9):911-6. PubMed ID: 15002010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.
    Collaborative Ocular Melanoma Study Group
    Ophthalmology; 2007 Jul; 114(7):1363-71. PubMed ID: 17337065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of Iodine-125 radiotherapy in the treatment of uveal melanoma].
    Caminal Mitjana JM; Quintana Casany M; Pera Fábregas J; Cinos Cope C; Guedea F
    Arch Soc Esp Oftalmol; 2002 Jan; 77(1):29-38. PubMed ID: 11813118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late complications after brachytherapy of I-125 uveal melanoma].
    Kowal J; Romanowska-Dixon B
    Klin Oczna; 2016; 118(3):226-30. PubMed ID: 30088387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P; Kivelä T
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
    Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
    Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radiation optic neuropathy after the brachytherapy of the uveal melanoma].
    Szuścik I; Romanowska-Dixon B; Markiewicz A; Pogrzebielski A; Jakubowska B
    Klin Oczna; 2006; 108(7-9):278-80. PubMed ID: 17290823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
    Bacin F; Kwiatkowski F; Dalens H; Rozan R; Gagyi S; Donnarieix D; Bard JJ; Robert JL
    J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma.
    Bianciotto C; Shields CL; Pirondini C; Mashayekhi A; Furuta M; Shields JA
    Ophthalmology; 2010 May; 117(5):1005-12. PubMed ID: 20079924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
    Krema H; Xu W; Payne D; Vasquez LM; Pavlin CJ; Simpson R
    Can J Ophthalmol; 2011 Apr; 46(2):158-63. PubMed ID: 21708084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.
    Tarmann L; Wackernagel W; Ivastinovic D; Schneider M; Winkler P; Langmann G
    PLoS One; 2017; 12(8):e0183833. PubMed ID: 28859118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early macular morphological changes following plaque radiotherapy for uveal melanoma.
    Horgan N; Shields CL; Mashayekhi A; Teixeira LF; Materin MA; Shields JA
    Retina; 2008 Feb; 28(2):263-73. PubMed ID: 18301032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid exudation following plaque radiotherapy for posterior uveal melanoma.
    Mills MD; Harbour JW
    Am J Ophthalmol; 2006 Mar; 141(3):594-595. PubMed ID: 16490526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.
    Krema H; Heydarian M; Beiki-Ardakani A; Weisbrod D; Xu W; Laperriere NJ; Sahgal A
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):510-5. PubMed ID: 23507292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.